When Onward was first diagnosed with chronic myeloid leukemia (CML), he spent many sleepless nights thinking about his future. Now, 11 years later, he advocates and provides support for other people going through the same thing.
“I am now living a normal life and enjoying my cycling, and gardening, and forgetting about CML, I only remember that I am a patient when it’s time to take my medication,” he said. “I now have hope, and I am able to instill hope to newly diagnosed patients.”
Onward is a 45-year-old farmer living in Zimbabwe with his wife, Tabeth, and their four children. In 2014, he started feeling weak and losing weight, and noticed he couldn’t cycle as far.
Onward said it took a while to be diagnosed then because the blood samples had to be taken to South Africa. He also had to sell his only car and furniture to afford the tests. Finally, a doctor confirmed that he had CML.
“My wife was so young at that stage, and I was just jealous and scared of losing her to someone else or not being able to grow old with her,” he said. “It wasn’t easy to accept.”
The doctor said medication was expensive, so he recommended our program. The Max Foundation and its partners provide access to treatment free of charge. After treatment, Onward started feeling better. He said every time he went for a checkup, there was good news.
In 2015, after encouragement from a Max team member, Onward became one of four founding members of the CML Zimbabwe Trust. They provide support, comfort, and education for patients. Currently, they’re letting people know about the transportation grants from Max to motivate them to seek treatment.
“I would like to thank the Max Foundation for the donation of the medication, which saves hundreds of patients in my country,” Onward said.
In 2022, Onward and Tabeth welcomed their fourth child, a son. Although he lost sleep over his diagnosis, Onward said he’s now proud to share his story and pass hope along to others.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
Shining a Light on Salsabila’s Ambition
Cancer impacts entire families, not just the person receiving the diagnosis. Salsabila was 16 when she found out her father had marginal zone lymphoma. She’s the eldest of three siblings, living with her family in Malaysia. Navigating her father Mr. Azmi’s symptoms and treatment was difficult for them. Despite these challenges, Salsabila continued to study….
Building a Cancer Coalition in Guatemala
In Guatemala, there are 14,200 new cases of cancer a year and from this amount 9,100 people die of cancer or 64.7%. Most of these diagnoses could have been prevented or better treated if diagnosed early. In Guatemala only the persons who have access to the national social security plan have free services and treatment, but poor quality and lack of medications or in most occasions. People who do not have social security have to pay for health services and for medications. As per statistics taken from Globocan 2008, the most common cancers in Guatemala are prostate, cervix, stomach, breast and lung cancers.
The Max Foundation Joins Poptivism
The Max Foundation is joining Poptivism — a consumer-driven charitable giving program that sells unique PopSocket Grips and donates 50% of the sales of those PopGrips to support a nonprofit’s mission (that’s us!). Please consider purchasing one of our Poptivism PopGrips today! With each purchase, you’ll help expand access to lifesaving cancer treatment the world over.
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.